5368-28-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Phenylpiperazin-2-one is used as a pharmaceutical intermediate for the development of biologically active molecules, leveraging its interactions with neurotransmitter receptors in the brain.
Used in Medical Research:
3-Phenylpiperazin-2-one is used as a research compound for investigating its potential application in the treatment of various medical conditions such as depression, anxiety, and addiction, due to its ability to modulate neurotransmitter receptor activity.
Used in Chemical Synthesis:
3-Phenylpiperazin-2-one is used as a building block in the synthesis of novel compounds with potential therapeutic properties, contributing to the development of new pharmaceuticals and therapeutic agents.

InChI:InChI=1/C10H12N2O/c13-10-9(11-6-7-12-10)8-4-2-1-3-5-8/h1-5,9,11H,6-7H2,(H,12,13)

Upstream product

• 107-15-3 ethylenediamine 
• 2882-19-1 ethyl 2-phenyl-2-bromoacetate 
• 2882-18-0 2-hydroxy-3-phenylpyrazine 
• 4870-65-9 2-bromophenylacetic acid 
• 1238539-07-5 tert-butyl (2-(2-bromo-2-phenylacetamido)ethyl)carbamate 
• 19078-72-9 bromo(phenyl)acetyl chloride 
• 117088-46-7 (E)-β-phenyl-α-(methylthio)vinyl p-tolylsulfone 
• 100-52-7 benzaldehyde 

Downstream Products

• 4502-71-0 1-methyl-6-phenyl-2,3,6,7-tetrahydro-1H-diazepin-5-one 
• 145729-86-8 2-phenyl-1-trimethylsilylmethylpiperazine 
• 145729-88-0 4-acetyl-2-phenyl-1-trimethylsilylmethylpiperazine 
• 5271-26-1 m-phenylpiperazine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 59622-56-9 4-(4-benzyloxy-benzyl)-3-phenyl-piperazin-2-one 
• 59622-81-0 1-(2-diethylamino-ethyl)-3-phenyl-4-(3-trifluoromethyl-benzyl)-piperazin-2-one 
• 26840-86-8 4-(3,4-dichloro-benzyl)-3-phenyl-piperazin-2-one 
• 59622-76-3 4-(2-chloro-benzyl)-1-(2-diethylamino-ethyl)-3-phenyl-piperazin-2-one 
• 1309367-37-0 2-phenyl-3-oxo-piperazine-1-carbodithioic acid 3-cyano-3,3-diphenylpropyl ester 

Relevant academic research and scientific papers

An Efficient Two-Step Preparation of α-, β-, γ- or δ-Amino Acids from 2-Pyrazinones, 2-Hydroxypyrimidines or 2-Pyridones Respectively

A practical and efficient two-step procedure is reported for the preparation of a variety of α-, β-, γ- and δ-amino acids from 2-pyridone, 2-pyrazinone or 2-hydroxypyrimidine and derivatives. The procedure is amenable to scale-up and in most cases no chromatographic purification of the product is required. This approach is useful, especially in the synthesis of amino acids or deuterated amino acids that are not obtained by other methods.

Application of piperazine structure containing compound to preparation of LSD1 (Lysine Specific Demethylase 1) inhibitor

The invention discloses application of a piperazine structure containing compound to the preparation of a histone lysine specific demethylase (LSD1) inhibitor. The structural general formula of the compound is as shown in the following descriptions (wherein, A is hydrogen, carbonyl or thiocarbonyl) or a configurational isomer and a pharmaceutical salt thereof, or is as shown in the following descriptions or a pharmaceutical salt thereof. The compound has an obvious inhibition effect on the LSD1, can be prepared into the LSD1 inhibitor, and is used for preventing and treating a disease related to the activity of the histone LSD1.

Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain

Novel 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists were optimized to allow for good blood-brain barrier permeability and high P2X7 target engagement in the brain of rats. Compound 25 (huP2X7 IC50 = 9 nM; rat P2X7 IC50

Synthesis and structure-activity relationships of A novel class of dithiocarbamic acid esters as anticancer agent

Based on a novel lead compound 4-methylpiperazine-1-carbodithioic acid 3-cyano-3,3-diphenylpropyl ester 1, the systematic structural modification was carried out. All the synthesized compounds were evaluated for their in-vitro anticancer activities on four to six different cell lines at three different concentrations. Most of the tested compounds could selectively inhibit the growth of HL-60 and Bel-7402 cell lines at a medium concentration. Four compounds (3f, 3g, 3n, and 5) were selected for the IC50 test, and the results revealed that three compounds (3g, 3n, and 5) showed almost the same or a slightly weaker activity than compound 1 against HL-60, and three compounds (3f, 3g, and 3n) showed >2-fold higher potency than compound 1 against Bel-7402. The in-vivo efficacy of 3n · HCl was evaluated with transplanted hepatocyte carcinoma 22 as an in-vivo test model. It was found that 3n · HCl could inhibit significantly the growth of tumor, and that this effect was dose-dependent. Meanwhile, the compound 3n · HCl showed low toxicity compared with compound 1 · HCl as evidenced by the little body-weight loss. These results confirmed that compound 3n · HCl is more potent than the lead compound 1 · HCl. Preliminary structure-activity relationships indicated that: a) Both nitrile group and the cyclic amine containing at least two nitrogens were indispensable moieties to keep the activity; b) substitution of the piperazine ring is unfavorable for the improvement of activity; c) the suitable linker joining the piperazinyl dithiocarboxyl and diphenylacetonitril group should be ethylene; d) a non-coplanar arrangement of the two benzene rings appears to be essential for activity. Based on a novel lead compound 4-methyl-piperazine-1-carbodithioic acid 3-cyano-3,3-diphenyl-propyl ester 1, the systematic structural modification was carried out. Compounds 3g and 3n were found to show more potent biological activities than lead compound 1. Some useful SARs were revealed Copyright

Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process

Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: wherein: n is an integer of 1 to 6; X, Y, Z1 and Z2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C1-C6) alkoxy, N-alkyl,(C2-C6) acyloxy, N-alkylene, —SH, —SR, wherein R is from the same group as R1 and R2 and can be the same or different than R1 and R2, amino, nitro, cyano, hydroxy, C(═O) OR6, —C(═O) NR5R4, NR3R2, or S(αO)k R1 wherein k is 1 or 2, and R1 to R6 are independently hydrogen or (C1-C6) alkyl; R1, and R2 can be the same or different and are hydrogen, (C1-C6) alkyl, hydroxyalkyl or mercaptoalkyl, —C(═O) OR1, cyano, (C1-C6) alkenyl, (C2-C6) alkynyl, or 1,2,4-oxadiazol-5-yl optionally substituted at the 3-position by Z4 wherein any (C1-C6) alky, (C1-C6) alkanoyl, (C2-C6) alkenyl or (C2-C6) alkynyl can optionally be substituted by 1, 2 or 3 Z; R7 can be hydrogen, O or phenyl R8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl Z4 is (C1-C6) alkyl or phenyl, optionally substituted by 1, 2 or 3 Z1 W is O or S T is amino or C1-C6 aminoalkyl A is N or C T is C1-C6 alklyl or sulfonyl and V is alkyl (C0-C6), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R1 or R2 as indicated above and φ is phenyl, naphthyl, thienyl or pyridinyl.

DIAGNOSTIC AND THERAPEUTIC ALKYL PIPERIDINE/PIPERAZINE COMPOUNDS AND PROCESS

Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: (I), (II), (III), (IV), (V) wherein: n is an integer of 1 to 6; X, Y, Z1 and Z2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C1-C6)alkoxy, N-alkyl, (C2-C6)acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R1 and R2 and can be the same or different than R1 and R2, amino, nitro, cyano, hydroxy, C(=O)OR6, -C(=O)NR5R4, NR3R2, or S(=O)kR1 wherein k is 1 0r 2, and R1 to R6 are independently hydrogen or (C1-C6)alkyl; R1 and R2 can be the same or different and are hydrogen, (C1-C6)alkyl, hydroxyalkyl or mercaptoalkyl, -C(=O)OR1, cyano, (C1-C6)alkenyl, (C2-C6) alkynyl, or 1, 2, 4-oxadiazol-5-yl optionally substituted at the 3-position by Z4 wherein any (C1-C6)alky, (C1-C6)alkanoyl, (C2-C6)alkenyl or (C2-C6)alkynyl can optionally be substituted by 1, 2 or 3 Z; R7 can be hydrogen, O or phenyl; R8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl; Z4 is (C1-C6)alkyl or phenyl, optionally substituted by 1, 2 or 3 Z1; W is O or S; T is amino or C1-C6aminoalkyl; A is N or C; T is C1-C6alkyl or sulfonyl and V is alkyl (C0-C6), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R1 or R2 as indicated above and D is phenyl, naphrhyl, thienyl or pyridinyl.

Novell synthesis of α-amino carboxamides and their related compounds via α-oxo sulfones starting from 2,2-disulfonyloxiranes

2-(Methylsulfonyl)-2-(p-tolylsulfonyl)oxiranes 1 are easily prepared by the condensation of methylthiomethyl p-tolyl sulfone (MT-sulfone) with aldehydes and the subsequent oxidation with MCPBA. They smoothly reacted with 2 molar amounts of primary or seco

Processes and intermediates useful in the preparation of Cis 1,3,4,6,7 llb-Hexa-hydro-7-aryl-2H-pyrazino[2,1-a]isoquinolines

Process of preparing the cis isomeric form of pyrazino [2,1-a] isoquinolines of formula The process involves novel 2-piperazinones of formula and novel pyrazino [2,1-a] isoquinolines of formula